Attention Deficit Hyperactivity Disorder (ADHD) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Attention Deficit Hyperactivity Disorder (ADHD) – Drugs In Development, 2024 report and make more profitable business decisions.
Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity, and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination, and inability to sustain attention on tasks or activities. Treatment includes analeptics.
The Attention Deficit Hyperactivity Disorder (ADHD) drugs in development market research report provide comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Attention Deficit Hyperactivity Disorder (ADHD) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 68 molecules, with 65 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Attention Deficit Hyperactivity Disorder (ADHD) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Attention Deficit Hyperactivity Disorder (ADHD) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Attention Deficit Hyperactivity Disorder (ADHD) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3Z ehfAelis Farma SAS
AgoneX Biopharmaceuticals Inc
Altus Formulation Inc
Astrogen Ltd
Attentive Therapeutics Inc
Axsome Therapeutics Inc
BCWorld Pharm Co Ltd
Brillian Pharma Inc.
Cennerv Pharma (S) Pte Ltd
Cingulate Inc
Collegium Pharmaceutical Inc
Curemark LLC
DURECT Corp
Eddingpharm Inc
Emplicure AB
EncepHeal Therapeutics Inc
Ensysce Biosciences Inc
GRI Bio Inc
Hyloris Pharmaceuticals SA
INVENT Pharmaceuticals Inc
Kashiv BioSciences LLC
Lennham Pharmaceuticals Inc
LP Pharmaceutical (Xiamen) Co Ltd
M et P Pharma AG
Marvel Biotechnology Inc
Mind Medicine MindMed Inc
Mindset Pharma Inc
Monument Therapeutics Ltd
Neurocentria Inc
NeuroNascent Inc
NLS Pharmaceutics AG
NutriBand Inc
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
OWP Pharmaceuticals Inc
P2D Inc
Pediatrix Therapeutics Inc
PolyCore Therapeutics LLC
RespireRx Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Shanghai Ark Biopharmaceutical Co Ltd
Shenox Pharmaceuticals LLC
SK Life Science Inc
SUNY Upstate Medical University
Supernus Pharmaceuticals Inc
Suven Life Sciences Ltd
Tonix Pharmaceuticals Holding Corp
TRImaran Pharma Inc
Tris Pharma Inc
Vanderbilt University
Yichang Humanwell Pharmaceutical Co Ltd
Yuyu Pharma Inc
Zevra Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions